| 查看: 1072 | 回复: 1 | |||
| 当前主题已经存档。 | |||
huajieyu464木虫 (正式写手)
|
[交流]
新的治疗膝关节炎药物
|
||
|
Naproxcinod (formely HCT 3012) Inflammation in osteoarthritis - phase 3 Naproxcinod is NicOx’ lead product, in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. It is a unique nitric oxide-donating anti-inflammatory and the first of the CINOD class (COX-Inhibiting Nitric Oxide Donators). NicOx aims to develop naproxcinod as a powerful anti-inflammatory agent with no detrimental effects on blood pressure and good gastrointestinal tolerability and safety. Top-line results from the first phase 3 study were successful. This represents an important step towards NicOx’ goal of making naproxcinod the drug-of-choice for osteoarthritis patients. |
回复此楼» 猜你喜欢
2026年申博药学专业
已经有1人回复
-
药学专硕申博
已经有18人回复
-
药理学论文润色/翻译怎么收费?
已经有87人回复
-
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
医药研发数据库资源
已经有4人回复
-
分子对接相关经验分享
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
2026生物医药产业发展大会
已经有0人回复
-
国青中了
已经有23人回复
